Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;8(6):1009-18.
doi: 10.2215/CJN.09250912. Epub 2013 Mar 7.

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD

Tamara Isakova  1 , Allison Barchi-Chung, Gwen Enfield, Kelsey Smith, Gabriella Vargas, Jessica Houston, Huiliang Xie, Patricia Wahl, Eva Schiavenato, Austin Dosch, Orlando M Gutiérrez, Jorge Diego, Oliver Lenz, Gabriel Contreras, Armando Mendez, Rory B Weiner, Myles Wolf
Affiliations
Randomized Controlled Trial

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD

Tamara Isakova et al. Clin J Am Soc Nephrol. 2013 Jun.

Abstract

Background: Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited.

Design, setting, participants, & measurements: In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline.

Results: Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end.

Conclusion: The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.

Trial registration: ClinicalTrials.gov NCT00843349.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study design and flow of participants. (A) Study design. (B) Thirty-nine patients completed 3 months of interventions according to random assignment to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo, 900-mg phosphate (P) diet plus LC placebo, ad libitum diet plus LC and 900-mg P diet plus LC.
Figure 2.
Figure 2.
Average daily doses of lanthanum carbonate (LC) during the study. Mean ± SD dose of lanthanum carbonate throughout the study is shown for each treated group in relation to the protocol specified dose, indicated by the dashed horizontal gray line.
Figure 3.
Figure 3.
Combined effects of lanthanum carbonate (LC) and dietary intervention on fibroblast growth factor 23 (FGF23) and other markers of mineral metabolism according to four treatment groups. (A–D) Mean values for 24-hour urinary phosphate, serum phosphate, FGF23, and parathyroid hormone (PTH) throughout the study period. (E–H) Percentage changes in these measures from baseline.
Figure 4.
Figure 4.
Effects of lanthanum carbonate (LC) and dietary intervention on fibroblast growth factor 23 (FGF23) in individual participants according to four treatment groups. Percentage changes in FGF23 from baseline to end of study for individual patients.
See this image and copyright information in PMC

References

    1. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370–1378, 2011 - PMC - PubMed
    1. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group : Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432–2439, 2011 - PMC - PubMed
    1. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators : FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913–1922, 2011 - PMC - PubMed
    1. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25: 3983–3989, 2010 - PubMed
    1. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393–4408, 2011 - PMC - PubMed

Publication types

MeSH terms

Associated data